Understand the source comparison
GHRP-2 Acetate: Peptide Comparison
GHRP-2 Acetate GHS-R1a agonist (ghrelin receptor) Moderate-Strong (20–50% increase) High (5–10× baseline GH) 50–300 mcg High ghrelin receptor selectivity, minimal cortisol elevation GHRP-6 Strong (30–60% increase) Moderate-High (4–8× baseline GH) 100–400 mcg H
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHRP-2 Acetate
- GHS-R1a agonist (ghrelin receptor)
- Moderate-Strong (20–50% increase)
- High (5–10× baseline GH)
- 50–300 mcg
- High ghrelin receptor selectivity, minimal cortisol elevation
- GHRP-6
- Strong (30–60% increase)
- Moderate-High (4–8× baseline GH)
- 100–400 mcg
- Highest appetite stimulation, also activates peripheral ghrelin receptors
- Ipamorelin
- GHS-R1a agonist (selective)
- Minimal (5–15% increase)
- Moderate (3–5× baseline GH)
- 200–500 mcg
- Most selective GH release, lowest appetite/cortisol effects
- MK-677
- GHS-R1a agonist (oral)
- Moderate (15–35% increase)
- Sustained (24hr elevation)
- 10–25 mg oral
- Oral bioavailability, sustained release, moderate appetite stimulation
- GHRP-2 sits in the middle of the growth hormone-releasing peptide spectrum—more appetite-stimulating than ipamorelin but less than GHRP-6, with potent GH release comparable to GHRP-6 but without the pronounced cortisol/prolactin elevation. For researchers specifically targeting appetite stimulation, GHRP-6 produces stronger effects, but GHRP-2 offers a better balance when appetite stimulation and growth hormone dynamics both matter to the study design. Ipamorelin is the preferred choice when GH release is the primary endpoint and appetite changes would confound results.